
Overview
Delpharm Poznań is a leading CDMO specializing in the development and manufacturing of pharmaceuticals for the pharmaceutical industry. The company offers expertise in solid, sterile, semi-solid, and liquid forms, with a particular focus on nasal spray production, providing flexible manufacturing capabilities and diverse packaging options. Delpharm operates multiple production sites in Europe and North America, ensuring high-quality and compliant therapeutic solutions.
Financials
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
From the notes
| Current income tax (CIT due) | $928,065 | |
| Profit allocation | No decision | |
| Capital expenditure | $4,204,493 | |
| Planned capital expenditure (next year) | $6,654,947 | |
| Foreign sales | 99.21% of revenue ($105,830,435) | |
| Revenue structure | Wyroby gotowe |
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 88 days late). All were audited by a statutory auditor.
- 202524/11/2025
- 202410/12/2024
- 202321/12/2023
- 202111/10/2022
- 202030/09/2021
- 201908/09/2020
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Delpharm will attend the American Pharma Manufacturing & Outsourcing Summit 2026

Delpharm will attend the American Pharma Manufacturing & Outsourcing Summit 2026

Delpharm to attend the American Pharma Manufacturing & Outsourcing Summit 2026

Delpharm will attend the American Pharma Manufacturing & Outsourcing Summit 2026
Delpharm will be attending the American Pharma Manufacturing & Outsourcing Summit 2026, taking place on November 19-20, 2026, at Encore Boston Harbor in Boston, Massachusetts.
Industry
Offer
- Drug development
- Medicine production
- Drug testing
- Pre-filled syringe filling
- Nasal spray manufacturing
- Liquid medicine manufacturing
Websites
- delpharm.comDelpharm - Fabrication développement de médicaments CDMO
Authorized Representatives
Manner of representation
To make declarations of will on behalf of the company and sign documents on its behalf, joint action by two members of the management board or one member of the management board jointly with a commercial proxy is required.
Supervisory board
Ownership
| Owner |
|---|
Delpharm Industrie Sas |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 1994-01-01.
55 1940 1210 0103 7732 0080 0000
41 1940 1210 0103 7732 0011 0000
68 1030 1508 0000 0005 0022 3189
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Land (incl. perpetual usufruct) | $5.7M$5,713,808 |
Buildings and premises | $41.9M$41,883,456 |
Secured liabilities
| Type | Secures | |
|---|---|---|
Pledge over the debtor’s assets | Lease of computer equipment |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Nov 23, 2021 | Commercial Companies Code notice | |
| Nov 4, 2021 | Demerger announced | |
| Dec 1, 2014 | Commercial Companies Code notice |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 7, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Starosta Powiatu Poznań | |
| Aug 3, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $18,166$18,166 | Zarządca Rozliczeń S.A. | |
| Aug 3, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $15,285$15,285 | Zarządca Rozliczeń S.A. |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| Waste generation | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo Farmaceutyczne S.A. | $160,174,284.28 | anpharm.pl | ||
| Biofarm sp. z o.o. | $143,422,260.45 | biofarm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne Polfa S.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| Przedsiębiorstwo Farmaceutyczne Lek-Am sp. z o.o. | $102,266,019.67 | lekam.pl | ||
| Natur Produkt Pharma sp. z o.o. | $93,854,070.54 | nppharma.pl | ||
| Chiesi Poland sp. z o.o. | $87,762,158.97 | chiesi.com | ||
| ICN Polfa Rzeszów S.A. | $85,044,250.03 | icnpolfa.pl | ||
| Orifarm Manufacturing Poland sp. z o.o. | $83,999,052.46 | orifarm.com | ||
| Synoptis Pharma sp. z o.o. | $79,311,000.88 | synoptispharma.pl | ||
| Przedsiębiorstwo Produkcyjno-Handlowe Ewa S.A. | $14,322,437.53 | ewa-sa.pl |
Change history
| Date | Event | |
|---|---|---|
| 2022-06-30 | Name change (Glaxosmithkline Pharmaceuticals → Delpharm Poznań) | |
| 2001-05-28 | Name change (Glaxo Wellcome → Glaxosmithkline Pharmaceuticals) | |
| 2001-05-25 | Entered in the register |
FAQ
Last updated: 2026-11-03